Polatuzumab vedotin and CD79B : A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma

Documenti analoghi

• Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma
  di: Tomotaka Suzuki, et al.
  Pubblicazione: (2025)
• Molecular characterization of diffuse large B‐cell lymphomas associated with hepatitis C virus infection
  di: Roberta Sciarra, et al.
  Pubblicazione: (2024)
• The importance of assessing the fitness of older patients with newly diagnosed diffuse large B‐cell lymphoma and classic Hodgkin lymphoma
  di: Vittorio Ruggero Zilioli, et al.
  Pubblicazione: (2025)
• Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
  di: Sean Harrop, et al.
  Pubblicazione: (2025)
• New standards of care for treatment of diffuse large B‐cell lymphoma
  di: Chathuri Abeyakoon, et al.
  Pubblicazione: (2024)